Loading company…
Zhisheng Biopharmaceutical develops large-molecule drugs, including FGF4 products for wound care and skin applications.
Founded in 2025 and based in Wenzhou, China, Zhisheng Biopharmaceutical researches and develops large-molecule drugs. Its products include an FGF4 drug for hard-to-heal wounds, pet medicine for skin ulcers and peptide raw materials for medical aesthetics. In June 2025, it raised venture funding from Zheshang Venture Capital to support product development, patent transfers and recruitment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in